MabVax Raising $4 Million

Bruce V. Bigelow9/2/09

MabVax Therapeutics, a San Diego biotech developing novel vaccines and human antibodies for the treatment of cancer, plans to raise $4 million from investors, according to a recent filing with the Securities and Exchange Commission. The company, which has raised about $500,000 so far, was founded in 2006 to develop polyvalent versions of existing monovalent vaccines against small cell lung cancer, sarcoma, melanoma, and other cancers. MabVax says it plans to develop fully human monoclonal antibody products at the same time.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788